User login
Key clinical point: Some biologic disease-modifying antirheumatic drugs (bDMARDs), especially anti-tumor necrosis factor (TNF) agents, may prevent radiographic progression in patients with psoriatic arthritis (PsA).
Major finding: Anti-TNF agents like infliximab (standardized mean difference [SMD], −0.59; 95% CI, −0.87 to −0.3), etanercept (SMD, −0.51; 95% CI, −0.78 to −0.23), and adalimumab (SMD, −0.45; 95% CI, −0.64 to −0.26) followed by interleukin inhibitors like ixekizumab (SMD, −0.37; 95% CI, −0.62 to −0.12) and secukinumab 300 mg (SMD, −0.33; 95% CI, −0.50 to −0.15) were more effective than placebo in reducing the total radiographic score for structural damage.
Study details: Finding are from a meta-analysis of 11 randomized controlled trials including 4,010 patients with PsA who received bDMARDs or placebo.
Disclosures: This study did not receive any external funding. CH Yang declared receiving speaking fees from several sources.
Source: Wang SH et al. Biologic disease-modifying antirheumatic drugs for preventing radiographic progression in psoriatic arthritis: A systematic review and network meta-analysis. Pharmaceutics. 2022;14(10):2140 (Oct 8). Doi: 10.3390/pharmaceutics14102140.
Key clinical point: Some biologic disease-modifying antirheumatic drugs (bDMARDs), especially anti-tumor necrosis factor (TNF) agents, may prevent radiographic progression in patients with psoriatic arthritis (PsA).
Major finding: Anti-TNF agents like infliximab (standardized mean difference [SMD], −0.59; 95% CI, −0.87 to −0.3), etanercept (SMD, −0.51; 95% CI, −0.78 to −0.23), and adalimumab (SMD, −0.45; 95% CI, −0.64 to −0.26) followed by interleukin inhibitors like ixekizumab (SMD, −0.37; 95% CI, −0.62 to −0.12) and secukinumab 300 mg (SMD, −0.33; 95% CI, −0.50 to −0.15) were more effective than placebo in reducing the total radiographic score for structural damage.
Study details: Finding are from a meta-analysis of 11 randomized controlled trials including 4,010 patients with PsA who received bDMARDs or placebo.
Disclosures: This study did not receive any external funding. CH Yang declared receiving speaking fees from several sources.
Source: Wang SH et al. Biologic disease-modifying antirheumatic drugs for preventing radiographic progression in psoriatic arthritis: A systematic review and network meta-analysis. Pharmaceutics. 2022;14(10):2140 (Oct 8). Doi: 10.3390/pharmaceutics14102140.
Key clinical point: Some biologic disease-modifying antirheumatic drugs (bDMARDs), especially anti-tumor necrosis factor (TNF) agents, may prevent radiographic progression in patients with psoriatic arthritis (PsA).
Major finding: Anti-TNF agents like infliximab (standardized mean difference [SMD], −0.59; 95% CI, −0.87 to −0.3), etanercept (SMD, −0.51; 95% CI, −0.78 to −0.23), and adalimumab (SMD, −0.45; 95% CI, −0.64 to −0.26) followed by interleukin inhibitors like ixekizumab (SMD, −0.37; 95% CI, −0.62 to −0.12) and secukinumab 300 mg (SMD, −0.33; 95% CI, −0.50 to −0.15) were more effective than placebo in reducing the total radiographic score for structural damage.
Study details: Finding are from a meta-analysis of 11 randomized controlled trials including 4,010 patients with PsA who received bDMARDs or placebo.
Disclosures: This study did not receive any external funding. CH Yang declared receiving speaking fees from several sources.
Source: Wang SH et al. Biologic disease-modifying antirheumatic drugs for preventing radiographic progression in psoriatic arthritis: A systematic review and network meta-analysis. Pharmaceutics. 2022;14(10):2140 (Oct 8). Doi: 10.3390/pharmaceutics14102140.